Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

The Medical Devices business remained a standout performer at Abbott, with Q4 sales up 12.3% to $5.68 billion. Abbott ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

Abbott Laboratories (ABT) on Thursday reported fourth-quarter net income of $1.78 billion. The Abbott Park, Illinois-based ...

Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...

Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King ...

Abbott’s latest CE mark for its TactiFlex Duo system was based on a clinical trial conducted in the European Union, United ...